Linezolid is superior to vancomycin in experimental pneumonia caused by Superantigen-Producing staphylococcus aureus in HLA class II transgenic mice

Antimicrob Agents Chemother. 2012 Oct;56(10):5401-5. doi: 10.1128/AAC.01080-12. Epub 2012 Jul 30.

Abstract

Superantigens (SAg), the potent activators of the immune system, are important determinants of Staphylococcus aureus virulence and pathogenicity. Superior response to SAg in human leukocyte antigen (HLA)-DR3 transgenic mice rendered them more susceptible than C57BL/6 mice to pneumonia caused by SAg-producing strains of S. aureus. Linezolid, a bacterial protein synthesis inhibitor, was superior to vancomycin in inhibiting SAg production by S. aureus in vitro and conferred greater protection from pneumonia caused by SAg-producing staphylococci.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / therapeutic use*
  • Animals
  • Linezolid
  • Mice
  • Mice, Inbred BALB C
  • Mice, Transgenic
  • Oxazolidinones / therapeutic use*
  • Pneumonia, Bacterial / drug therapy*
  • Staphylococcal Infections / drug therapy*
  • Staphylococcus aureus / drug effects*
  • Staphylococcus aureus / pathogenicity*
  • Superantigens / metabolism*
  • Vancomycin / therapeutic use*

Substances

  • Acetamides
  • Oxazolidinones
  • Superantigens
  • Vancomycin
  • Linezolid